

Supplementary Table 6. *p*-values comparing IgG, IgM, and IgA levels over time in HD patients and controls (data presented in Figure 3).

p-value*			All		27-70y		71-96y	
	Isotype	Time	t0	t1	t0	t1	t0	t1
Patients	IgG	t1	2.2x10 ⁻¹⁶	-	6.2x10 ⁻¹²	-	2.7x10 ⁻¹⁰	-
		t2	2.2x10 ⁻¹⁶	2.2x10 ⁻¹⁶	2.0x10 ⁻¹²	2.0x10 ⁻¹²	5.5x10 ⁻¹⁴	5.5x10 ⁻¹⁴
	Controls	t1	2.2x10 ⁻¹⁶	-	2.0x10 ⁻¹²	-	7.5 x10 ⁻¹³	-
		t2	2.2x10 ⁻¹⁶	2.2x10 ⁻¹⁶	2.0x10 ⁻¹²	2.0x10 ⁻¹²	4.4 x10 ⁻¹⁴	4.4 x10 ⁻¹⁴
Patients	IgM	t1	8.7x10 ⁻¹³	-	9.3x10 ⁻⁶	-	1.9x10 ⁻⁸	-
		t2	2.2x10 ⁻¹⁶	4.5x10 ⁻¹⁵	7.1x10 ⁻¹²	1.7x10 ⁻⁸	2.3x10 ⁻¹¹	8.8x10 ⁻⁸
	Controls	t1	0.0602	-	1.3x10 ⁻⁸	-	0.0004	-
		t2	0.00005	0.0405	1.1x10 ⁻⁸	0.07163	0.3502	0.2372
Patients	IgA	t1	2.2x10 ⁻¹⁶	-	1.8x10 ⁻¹¹	-	1.4x10 ⁻¹²	-
		t2	2.2x10 ⁻¹⁶	2.2x10 ⁻¹⁶	3.4x10 ⁻¹²	1.0x10 ⁻¹⁰	1.1x10 ⁻¹³	7.8x10 ⁻¹³
	Controls	t1	3.3x10 ⁻¹⁶	-	3.2x10 ⁻¹²	-	3.2x10 ⁻⁶	-
		t2	3.3x10 ⁻¹⁶	2.3x10 ⁻¹¹	3.2x10 ⁻¹²	0.0181	1.3x10 ⁻¹²	5.4x10 ⁻¹⁰

t0 – sera collected on day of 1st vaccine dose; t1 – sera collected 21 days post-1st vaccine dose.

*Pairwise Wilcoxon signed-rank test was used to compare Ig levels between time points.